SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement in Function and Activities of Daily Living in Patients with Chronic Traumatic Brain Injury
Retrieved on:
Tuesday, April 5, 2022
Research, Surgery, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Hospital, Regenerative medicine, Stroke, Trial of the century, American Academy of Neurology, Death, Sakigake, Traumatic brain injury, Disability, Global Burden of Disease Study, Veni, vidi, vici, Central nervous system, Bone marrow, Disease, MHLW, Patient, Incidence, Ministry of Health, Labour and Welfare, Medical director, FMMS, Food, Glasgow Outcome Scale, SL, TBI, Quality of life, Stem cell, Safety, Review, Headache, Person, New England Center for Investigative Reporting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, American Academy, Physical, AAN, FDA, INN, Pharmaceutical industry, Health insurance, Medical device, Meat, Health, Neurology, SB623, TRAUMATIC BRAIN INJURY, THE STEMTRA TRIAL, SANBIO
These findings reinforce the potential for SB623 to provide clinically meaningful improvements in motor function and ability to resume daily activities.
Key Points:
- These findings reinforce the potential for SB623 to provide clinically meaningful improvements in motor function and ability to resume daily activities.
- These improvements in motor impairment were maintained up to 48 weeks in the treatment group.
- SanBio is preparing to initiate a Phase 3 trial for SB623 in the United States, where many traumatic brain injury patients currently live.
- SB623 is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and ischemic stroke.